Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

1131898

	registered interest
	date	12/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	International Life Sciences Institute
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, following the publication of the study on the International Life Sciences Institute "Are industry-funded charities promoting “advocacy-led studies” or “evidence-based science”?, whether they classify the International Life Sciences Institute as an industry lobby group or a scientific health charity.
	tabling member printed	The Countess of Mar
	uin	HL16316
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The Department funds research via the National Institute for Health Research (NIHR). The NIHR does not itself classify any organisation in terms of charitable status or lobby group. The NIHR regards a charity as a specific type of voluntary organisation which must conform to the regulations set out in charity law particularly the Charities Act 2011. Charity is a legal status for an organisation, not a legal form or organisational structure.</p><p>Any organisation which considers that it can carry out high-quality clinical, applied health or social care research is likely to be eligible for Departmental, NIHR-funded research programmes, either directly or with a partner. There are specific guidance documents setting out eligibility criteria for the NIHR’s programmes which include information on partnership working, funding mechanism and contractual obligations including reporting and disclosure of conflicts of interest.</p> answering member printed Baroness Barran question first answered 26/06/2019 13:13:51 answering member 4703 label Biography information for Baroness Barran
	tabling member	1861 label Biography information for The Countess of Mar

1128009

	registered interest
	date	21/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what processes are in place to safeguard children with chronic fatigue syndrome and other disorders whose parents have enrolled them on Lightning Process courses; and what evaluation has been undertaken of the (1) benefits, and (2) harms, to those children who have participated in such courses.
	tabling member printed	The Countess of Mar
	uin	HL15894
	answer	answer is ministerial correction date of answer 05/06/2019 answer text <p>The Lightning Process (LP) is not offered as a part of the chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) standard treatments on the National Health Service. Subject to the nature of the safeguarding concerns, issues should be directed to the relevant professional regulator, should the practitioner be a member of a registered profession; the local authority (trading standards office or children’s service), if false claims are being made about the effectiveness of the treatment or welfare of a child is a concern; or the police, if a crime is involved.</p><p>The LP involves a course of three half-days of training aiming to teach participants how to use their brain to improve their body's health.</p><p>A randomised controlled trial with 100 adolescents aged 12-18 was undertaken by researchers in Bristol. Participants were randomised into two groups: those who received standard CFS/ME treatment and those who received the standard treatment plus the LP.</p><p>Researchers found those who received the LP had better physical function, were less tired and less anxious after six months. At 12 months, they had further improvement in physical function, and improved depression scores and school attendance. This research trial had several limitations as set out in the peer reviewed journal article. This was a very small trial and so it would need to be repeated in a much larger group to demonstrate more generalisable findings. Participants were not blinded so their self-reported outcomes might have been biased, for example participants may have been more likely to report positive outcomes because they knew they were getting additional therapy in the LP group. Of all those eligible to participate in the trial, fewer than 30% agreed to take part. Participants in the trial did not have any serious adverse events attributable to either LP or usual care. LP therapy was given in addition to the usual CFS/ME care as a no-treatment control group was not deemed ethical, therefore it cannot be suggested as a replacement for current specialised medical care.</p><p>Independent ethical review ensures that participant safety is at the centre of all research. In the United Kingdom, review by an ethics committee is one of a series of safeguards intended to protect the people taking part in the research. The operating procedure for trials in the UK has inbuilt safeguards designed to protect patients from harm in the event an intervention is ineffective or potentially harmful. Participants are free to withdraw from a study at any time.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 05/06/2019 16:40:17 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1861 label Biography information for The Countess of Mar

1131897

	registered interest
	date	12/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Food Standards Agency: Public Appointments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government when they intend to approve the appointment of a Chief Executive for the Food Standards Agency; and what has been the cause of the delay.
	tabling member printed	The Countess of Mar
	uin	HL16315
	answer	answer is ministerial correction date of answer 26/06/2019 answer text <p>The appointment is subject to the approval process which governs the Civil Service Commission Recruitment Principles. An announcement will be made once that process has concluded.</p> answering member printed Baroness Blackwood of North Oxford question first answered 26/06/2019 12:11:36 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1861 label Biography information for The Countess of Mar

1135740

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will place a copy of the World Health Organisation Global Advisory Committee on Vaccine Safety 2019 review of HPV vaccine safety in the Library of the House.
	tabling member printed	The Countess of Mar
	uin	HL16833
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>A meeting was held by the Global Advisory Committee on Vaccine Safety (GACVS) on 5 to 6 June 2019. However, the Medicines and Healthcare products Regulatory Agency is not aware of any formal review of human papillomavirus vaccine safety published by GACVS in 2019.</p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:24:58 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1861 label Biography information for The Countess of Mar

1135741

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mefloquine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the European Medicines Agency Pharmacovigilance Risk Assessment Committee’s 2014 report on the toxicity of mefloquine (Larium).
	tabling member printed	The Countess of Mar
	uin	HL16834
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>At its meeting in February 2014, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended that the product information for mefloquine (Lariam) be amended to state that neuropsychiatric adverse reactions may persist for months, or longer, even after discontinuation of the drug. The Medicines and Healthcare products Regulatory Agency (MHRA) accepted the recommendations and implemented the advice of the PRAC, which is reflected in the United Kingdom product information for mefloquine. In addition, the MHRA has since taken further action to ensure that these risks are adequately conveyed to UK prescribers and patients in the form of improved checklists for healthcare professionals and a patient alert card.</p> answering member printed Baroness Blackwood of North Oxford question first answered 10/07/2019 15:26:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1861 label Biography information for The Countess of Mar

1135743

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mattresses: Fire Resistant Materials
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the risks to the neurological development of (1) foetuses, and (2) new-born children, of exposure to polyurethane mattresses treated with chlorinated phosphate flame retardants.
	tabling member printed	The Countess of Mar
	uin	HL16836
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment has considered the evidence on the potential effects of chlorinated and non-chlorinated phosphate flame retardants from all exposure sources, in general. The Committee is preparing a statement on phosphate-based flame retardants and the potential for neurodevelopmental toxicity. It is expected that the statement will be published in summer 2019.</p><p>Chlorinated organophosphorous flame retardants are regulated under the European Union REACH (Restriction, Evaluation, Authorisation and Restriction of Chemicals) regime. The United Kingdom has been proactive in supporting the regulation of flame retardants through REACH. The European Chemicals Agency has announced an intention to restrict a number of chlorinated flame retardants. It is expected that the restriction proposal will be submitted in July 2019, followed by a public consultation.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:24:38 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1861 label Biography information for The Countess of Mar

825298

	registered interest
	date	17/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Records
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what remedy there is when a hospital trust persistently refuses to release full medical records to a patient or a GP for the patient under the Access to Medical Records Act 1990 and the Data Protection Act 1998 and may have destroyed some of those records despite their being protected on police advice.
	tabling member printed	The Countess of Mar
	uin	HL4831
	answer	answer is ministerial correction date of answer 25/01/2018 answer text <p>Patients have a legal right to apply for access to their medical records. A request for medical records should be made directly to the healthcare provider that provides the treatment. However, information can be exempt from disclosure if it “would be likely to cause serious harm to the physical or mental health or condition of the data subject or any other person”.</p><p> </p><p>An individual can complain to the Information Commissioner (ICO) about the data controller if they disagree with the decision to withhold records, or that this was not done in accordance with the legislation. Similarly, if records that should have been retained have been destroyed or deleted, this can be raised as part of a complaint to the ICO.</p><p> </p><p>From an Information Governance perspective, there are provisions with the current Data Protection Act 1998 and under discussion in the Data Protection Bill that allow the data subject (patient) to seek redress.</p> answering member printed Lord O'Shaughnessy question first answered 25/01/2018 16:26:42 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

857589

	registered interest
	date	07/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mefloquine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answer by Lord O'Shaughnessy on 18 January (HL4484), whether they consider the completed "cases of suicide", listed in the current mefloquine product information leaflet as reported psychiatric adverse reactions to the drug, to be permanent.
	tabling member printed	The Countess of Mar
	uin	HL6161
	answer	answer is ministerial correction date of answer 21/03/2018 answer text <p>In the context of an adverse reaction to a medicine, suicide is a possible outcome of suicidal ideation, rather than necessarily an adverse reaction to treatment. For mefloquine, the current assessment, as recommended by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee, is that whilst psychiatric side effects, including suicidal ideation, may persist after stopping treatment, current evidence does not support that these may be permanent after stopping treatment.</p> answering member printed Lord O'Shaughnessy question first answered 21/03/2018 15:46:39 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

885894

	registered interest
	date	17/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they intend to replace the phrase "medically unexplained symptoms" in the Improving Access to Psychological Therapies programme guidance if the World Health Organization decides it will no longer use this term; and if so, what terminology will be used instead.
	tabling member printed	The Countess of Mar
	uin	HL6990
	answer	answer is ministerial correction date of answer 01/05/2018 answer text <p>NHS England advises that, should the World Health Organization replace the phrase “medically unexplained symptoms” with an alternative phrase, it would make an assessment at that time as to whether, when and how to implement any change.</p><p> </p><p>Currently NHS England has not been made aware of any intended change to the current phrase by the World Health Organization.</p> answering member printed Lord O'Shaughnessy question first answered 01/05/2018 11:32:53 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar

890727

	registered interest
	date	24/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Chronic Fatigue Syndrome: Medical Treatments
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government why the NHS Choices website includes an article on the Lightning Process when this treatment is not available on the NHS.
	tabling member printed	The Countess of Mar
	uin	HL7246
	answer	answer is ministerial correction date of answer 08/05/2018 answer text <p>In addition to providing an overview of the symptoms, diagnosis and treatment of a wide range of conditions, NHS Choices also seeks to provide a balanced view of emerging, new or controversial treatments that are reported in the press, to help the public understand the facts of the story. In September 2017 the ‘Behind the headlines’ section of the NHS Choices website included a piece on the Lightning Process for treating chronic fatigue syndrome, following national press coverage which reported the findings of trial of this treatment.</p> answering member printed Lord O'Shaughnessy question first answered 08/05/2018 13:45:46 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	1861 label Biography information for The Countess of Mar